<PAGE> 1
U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-QSB
QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED MARCH 31, 1999
COMMISSION FILE NO. 0-24972
INKINE PHARMACEUTICAL COMPANY, INC.
(Exact name of small business issuer as specified in its charter)
NEW YORK 13-3754005
(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)
SENTRY PARK EAST
1720 WALTON ROAD
BLUE BELL, PA 19422
(Address of principal executive offices)
610-260-9350
(Issuer's telephone number)
Check whether the issuer (1) filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such
shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. Yes X No
At May 13, 1999, the registrant had outstanding 22,879,425 shares of common
stock, par value $.0001 per share.
Transitional Small Business disclosure format: Yes No X
<PAGE> 2
INKINE PHARMACEUTICAL COMPANY, INC.
TABLE OF CONTENTS
<TABLE>
<CAPTION>
PAGE
----
<S> <C>
PART I - FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
BALANCE SHEETS - as of March 31, 1999 (unaudited)
and June 30, 1998.................................................................... 3
STATEMENTS OF OPERATIONS (unaudited) -- For the Three
and Nine Month Periods Ended March 31, 1999 and 1998, and the
Period from July 1, 1993 (Commencement of Operations) through
March 31, 1999....................................................................... 4
STATEMENTS OF CASH FLOWS (unaudited) -- For the Nine Month
Periods Ended March 31, 1999 and 1998, and the Period from July 1, 1993
(Commencement of Operations) through March 31, 1999.................................. 5
NOTES TO UNAUDITED FINANCIAL STATEMENTS.............................................. 6
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATION................................................... 8
PART II - OTHER INFORMATION....................................................................... 11
SIGNATURES........................................................................................ 12
</TABLE>
<PAGE> 3
PART I -- FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
INKINE PHARMACEUTICAL COMPANY, INC.
(a development stage company)
BALANCE SHEETS
(In thousands, except share amounts)
<TABLE>
<CAPTION>
MARCH 31, 1999 JUNE 30, 1998
-------------- -------------
ASSETS (UNAUDITED)
<S> <C> <C>
Current assets:
Cash and cash equivalents ...................... $ 2,300 $ 1,115
Short term investments ......................... 6,295 11,847
Prepaid expenses and other current assets ...... 121 214
-------- --------
Total current assets ....................... 8,716 13,176
Fixed assets, net ................................... 215 190
-------- --------
Total assets ............................... $ 8,931 $ 13,366
======== ========
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable and other accrued expenses .... $ 645 $ 246
-------- --------
Stockholders' equity:
Common stock, $.0001 par value; authorized 50,000,000
shares; issued 22,732,970 shares ............... 2 2
Less common stock held in treasury (16,515 shares) .. (37) (37)
Additional paid-in capital .......................... 31,075 30,954
Deferred compensation ............................... (2,977) (4,320)
Other comprehensive income .......................... 3 3
Deficit accumulated during the development stage .... (19,780) (13,482)
-------- --------
Total stockholders' equity ................. 8,286 13,120
-------- --------
Total liabilities and stockholders' equity . $ 8,931 $ 13,366
======== ========
</TABLE>
See accompanying notes to unaudited financial statements.
3
<PAGE> 4
INKINE PHARMACEUTICAL COMPANY, INC.
(a development stage company)
STATEMENTS OF OPERATIONS
(unaudited)
(In thousands, except per share amounts)
<TABLE>
<CAPTION>
PERIOD FROM
JULY 1, 1993
(COMMENCEMENT
OF OPERATIONS)
THREE MONTHS ENDED NINE MONTHS ENDED THROUGH
MARCH 31 MARCH 31 MARCH 31
1999 1998 1999 1998 1999
-------- -------- -------- -------- --------------
<S> <C> <C> <C> <C> <C>
Costs and Expenses:
Research and development .... $ 1,768 $ 693 $ 4,052 $ 1,497 $ 8,230
Purchased research and
development ............ -- 72 -- 3,952 3,952
General and administrative ... 849 1,008 2,677 2,656 8,890
Write-off debt discount ...... -- -- -- -- 75
-------- -------- -------- -------- --------
Loss from operations ............... (2,617) (1,773) (6,729) (8,105) (21,147)
-------- -------- -------- -------- --------
Interest income .................... 116 201 431 327 1,374
Interest expense ................... -- -- -- -- (7)
-------- -------- -------- -------- --------
Basic and diluted net loss ......... $ (2,501) $ (1,572) $ (6,298) $ (7,778) $(19,780)
======== ======== ======== ======== ========
Basic and diluted net loss per share $ (0.11) $ (0.07) $ (0.28) $ (0.58)
Weighted average shares
Outstanding ................ 22,749 22,703 22,717 13,484
</TABLE>
See accompanying notes to unaudited financial statements.
4
<PAGE> 5
INKINE PHARMACEUTICAL COMPANY, INC.
(a development stage company)
STATEMENTS OF CASH FLOWS
(unaudited)
(In thousands)
<TABLE>
<CAPTION>
PERIOD FROM
JULY 1, 1993
NINE MONTHS ENDED (COMMENCEMENT OF
MARCH 31, OPERATIONS) THROUGH
1999 1998 MARCH 31, 1999
-------- -------- -------------------
<S> <C> <C> <C>
Cash flows from operating activities:
Net loss ...................................................... $ (6,298) $ (7,778) $(19,780)
Adjustments to reconcile net loss to
net cash used in operating activities:
Depreciation .............................................. 42 26 196
Write-off of debt discount ................................ -- -- 75
Value of services paid by options and warrants ............ -- -- 80
Amortization of deferred compensation ..................... 1,465 2,017 4,124
Purchased research and development ........................ -- 2,742 2,742
(Increase) decrease in prepaid expenses
and other assets ......................................... 93 176 (121)
Increase (decrease) in accounts payable
and accrued expenses ..................................... 399 65 671
Expenses paid by affiliate ................................ -- -- 97
Increase in management fees payable ....................... -- -- 113
-------- -------- --------
Net cash used in operating activities ....................... (4,299) (2,752) (11,803)
Cash flows from investing activities:
Purchases of investments ...................................... (9,930) (13,319) (32,373)
Proceeds from maturities and sales of investments ............. 15,481 1,160 26,085
Capital expenditures .......................................... (67) (201) (413)
-------- -------- --------
Net cash provided by (used in) investing activities ........ 5,484 (12,360) (6,701)
Cash flows from financing activities:
Issuance of common stock - net of expenses .................... -- 15,803 20,841
Cost of shares - acquired ..................................... -- -- (37)
Proceeds from notes payable - affiliates ...................... -- -- 14
Proceeds from notes payable - stockholders .................... -- -- 96
Proceeds from notes payable - other ........................... -- -- 300
Repayment of notes payable - stockholders and other ........... -- -- (410)
-------- -------- --------
Net cash provided by (used in) financing activities ......... -- 15,803 20,804
-------- -------- --------
Net increase in cash and cash equivalents ........................ 1,185 691 2,300
Cash and cash equivalents - beginning of period .................. 1,115 101 --
-------- -------- --------
Cash and cash equivalents - end of period ........................ $ 2,300 $ 792 $ 2,300
======== ======== ========
</TABLE>
See accompanying notes to unaudited financial statements.
5
<PAGE> 6
INKINE PHARMACEUTICAL COMPANY, INC.
(a development stage company)
NOTES TO FINANCIAL STATEMENTS
(unaudited)
1. BASIS OF PRESENTATION
The accompanying financial statements are unaudited and have been
prepared by InKine Pharmaceutical Company, Inc. (the "Company") in accordance
with generally accepted accounting principles.
Certain information and footnote disclosures normally included in the
Company's audited annual financial statements have been condensed or omitted in
the Company's interim financial statements. In the opinion of management, the
interim financial statements reflect all adjustments (consisting of normal
recurring adjustments) necessary for a fair representation of the results for
the interim periods presented.
The results of operations for the interim periods may not necessarily
be indicative of the results of operations expected for the full year, although
the Company expects to incur a significant loss for the year ending June 30,
1999. These interim financial statements should be read in conjunction with the
audited financial statements for the year ended June 30, 1998, which are
contained in the Company's most recent Annual Report on Form 10-KSB.
2. USE OF ESTIMATES
The preparation of the financial statements in conformity with
generally accepted accounting principles requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date(s) of the financial
statements and the reported amounts of revenues and expenses during the
reporting period(s). Actual results could differ from those estimates.
3. PRO FORMA FINANCIAL INFORMATION
As previously reported in the Company's reports filed under the
Securities Exchange Act of 1934 (the "Exchange Act"), as of November 6, 1997,
the Company acquired all the outstanding capital stock of CorBec
Pharmaceuticals, Inc. ("CorBec"), a privately owned, development-stage,
bio-pharmaceutical company founded in 1993 to discover and develop drugs to
treat autoimmune disease, serious infections and asthma/allergy, and Sangen
Pharmaceutical Company ("Sangen"), a privately owned, development-stage,
bio-pharmaceutical company formed in early 1997 and focused on the development
of a potential cancer treatment technology. CorBec's technology, which consists
of compounds designed to modulate the immune system, is licensed from the
University of Pennsylvania and has been developed in the laboratory of Alan D.
Schreiber, M.D., Professor of Medicine and Assistant Dean for Research at the
University of Pennsylvania School of Medicine (the "Fc Receptor Technology").
The most advanced product within this family of compounds, CBP-1011, is in Phase
III clinical trials for the treatment of idiopathic thrombocytopenic purpura
("ITP"). Sangen's technology consists of specific peptide molecules and a
polyclonal antibody developed by Dr. George Tuszynski, Professor of Surgery,
Medicine and Pathology at MCP Hahnemann University ("MCP"), based on a specific
thrombospondin receptor, which Dr. Tuszyuski discovered (the "Thrombospondin
Technology"). In addition, in early 1997, the Company acquired an exclusive,
worldwide license to a tablet form of the aqueous sodium phosphate purgative
formula used to clean the colon for any medical purpose and for use as a
laxative (the "Purgative Product"), which the company recently completed two
Phase III clinical trials for colonoscopies. The Company licensed this
technology from a partnership of physicians ("ALW Partnership"), including Craig
Aronchik, M.D., an attending gastroenterologist and Head of the Endoscopy Unit
at Pennsylvania Hospital in Philadelphia and a Clinical Associate Professor of
Medicine at the University of Pennsylvania School of Medicine. The acquisitions
of CorBec, Sangen and the Purgative Product license are referred to collectively
herein as the "Acquisitions."
Simultaneous with the Acquisitions, Dr. Leonard S. Jacob became
Chairman of the Board and Chief Executive Officer of the Company under a
long-term employment agreement and was issued a ten-year option entitling him to
purchase the number of shares of common stock of the Company (the "Common
Stock") equal to 7 -1/2% of the fully diluted capitalization of the Company. The
exercise price of Dr. Jacob's option is (i) $0.61 per share for 1,200,000 shares
and (ii) $1.00 per share for approximately 1,200,000 shares. Dr. Taffy J.
Williams,
6
<PAGE> 7
formerly the Company's President and Chief Executive Officer, became President
and Chief Operating Officer of the Company following the Acquisitions. In
January 1997, Dr. Williams received an option to purchase 5% of the fully
diluted capitalization of the Company. The exercise price of Dr. Williams'
option is (i) $0.61 per share for 500,000 shares and (ii) $1.00 per share for
approximately 1,000,000 shares. The exercise prices of Dr. Jacob's and Dr.
Williams' options were below market value of the Common Stock of the Company at
the time of grant. Therefore, the Company has incurred, and will continue to
incur, a significant non-cash charge to operations as a result of the option
grants.
The Sangen acquisition included the grant to Dr. Tuszynski and MCP of
125,000 shares of Common Stock of the Company and options to purchase an
aggregate of 375,000 shares, of which options for 250,000 shares will be
exercisable upon achievement of specified milestones in the development of a new
drug candidate. In addition, Dr. Tuszynski and MCP will be entitled to cash
royalties based on net sales and licensing fees derived from the technology. The
Company agreed to fund additional research in Dr. Tuszynski's laboratory in an
amount ranging from $150,000 (in the first year) to $1,350,000 (over seven
years, inclusive). Dr. Tuszynski is to be engaged as a consultant to the Company
for a two-year period beginning November 6, 1997, at a fee of $50,000 per year.
The acquisition of CorBec resulted in the payment of $750,000 and the
issuance of 750,000 shares of Common Stock of the Company with provisions for
additional cash payments and stock issuances based upon the achievement of
certain milestones for CBP-1011. In addition, the Company has agreed to enter
into three-year consulting agreements with Dr. Alan Schreiber, the inventor of
the Fc Receptor Technology, and with the former chief executive officer of
CorBec, providing for aggregate consulting fees over three years equal to
$405,000, and for the grant of options with respect to an aggregate of 170,000
shares of Common Stock. The Company is also to fund up to $240,000 of sponsored
research in Dr. Schreiber's laboratory over the course of three years beginning
November 6, 1997.
The following unaudited pro forma information is presented for the
Acquisitions, as if the Acquisitions had occurred on July 1, 1996. The pro forma
information does not purport to be indicative of the results that would have
been attained if the Acquisitions had actually been effective during the periods
presented, excludes the non-recurring purchased research and development charge
of $3,952,000, and is not necessarily indicative of operating results to be
expected in the future.
PRO FORMA INFORMATION AS IF THE ACQUISITIONS OCCURRED ON JULY 1, 1996
<TABLE>
<CAPTION>
For the nine months ended
March 31,
1998
-------------------------
<S> <C>
Costs and expenses ............................ $ 5,051,000
Net loss ...................................... 4,724,000
Shares used in computing loss per share........ 14,241,000
Net loss per share ............................ $0.33
</TABLE>
4. ACCOUNTING PRINCIPLES
Effective July 1, 1998, the Company adopted Statement of Financial
Accounting Standards No. 130, "Reporting Comprehensive Income". This Statement
requires that all items recognized under accounting standards as components of
comprehensive earnings be reported in an annual financial statement that is
displayed with the same prominence as other annual financial statements. This
Statement also requires that an entity classify items of other comprehensive
earnings by their nature in an annual financial statement. For example, other
comprehensive earnings may include foreign currency translation adjustments,
minimum pension liability adjustments and unrealized gains and losses on
marketable securities classified as available-for-sale. Annual financial
statements for prior periods will be reclassified as required. The Company's
total comprehensive earnings equaled its net income for the quarter and year to
date ending March 31, 1999.
7
<PAGE> 8
ITEM 2 MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
This report contains, in addition to historical information, statements
by the Company with regard to its expectations as to financial results and other
aspects of its business that involve risks and uncertainties and may constitute
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Such statements reflect management's current
views and are based on certain assumptions. Actual results could differ
materially from those currently anticipated as a result of a number of factors,
including, but not limited to, the risks and uncertainties discussed in this
report as well as those discussed under "Other Factors to be Considered" and
"Management's Discussion and Analysis of Financial Condition and Results of
Operations" of the Company's Annual Report on Form 10-KSB for the fiscal year
ended June 30, 1998 as filed with the Securities and Exchange Commission.
GENERAL
The Company is a biopharmaceutical company engaged in the development
of technologies for the diagnosis and treatment of cancer and autoimmune
diseases. The Company pursues these objectives through a technology platform
consisting of the Fc Receptor Technology, the Thrombospondin Technology and the
Purgative Product. The Company acquired these technologies in 1997. See Note 3
of the Notes to Unaudited Financial Statements.
Since commencing operations in 1993, the Company has not generated any
sales revenue. The Company has funded operations primarily from the proceeds of
public and private placements of securities. The Company has incurred net losses
in each year since its inception, and expects to incur additional losses for the
next several years. The Company expects that losses will fluctuate from quarter
to quarter, and that such fluctuations may be substantial. At March 31, 1999,
the Company's accumulated deficit was approximately $19,780,000.
RESULTS OF OPERATIONS
The Company incurred losses of $2,501,000 or $(0.11) per share, and
$6,298,000, or $(0.28) per share, for the three and nine month periods ended
March 31, 1999, respectively. The Company had net losses of $1,572,000, or
$(0.07) per share, and $7,778,000, or $(0.58) per share, for the same periods, a
year ago. Losses are expected to continue in the remainder of the fiscal year as
the Company develops the Purgative Product, Thrombospondin Technology and Fc
Receptor Technology.
Research and development expenses amounted to $1,768,000 and $4,052,000
for the three and nine month periods ended March 31, 1999, respectively, as
compared to $693,000 and $1,497,000 for the three and nine month periods ended
March 31, 1998, respectively. The increase in research and development expenses
is the result of conducting a pivotal Phase III clinical trial for the Company's
drug candidate, CBP-1011, and a pivotal Phase III clinical trial of Diacol(TM),
the Purgative Product. Research and development expenses are expected to
continue to increase in future quarters as the Company conducts its clinical
trials of CBP 1011 and also incurs additional manufacturing development costs
and regulatory costs of the Purgative Product.
In 1997, the Company incurred a one-time charge to earnings of
$3,952,000 for purchased research and development as a result of the Company's
acquisition of the Fc-Receptor Technology and the Thrombospondin Technology.
General and administrative expenses decreased in the three months ended
March 31, 1999 as compared to the same period a year ago due principally to
reorganization costs incurred in Fiscal Year 1998 related to the acquisition of
the technologies. General and administrative expenses remained constant for the
nine month period ended March 31, 1999 as compared to the same period a year
ago. Included in general and administrative expenses is amortization of options
previously granted to certain executive officers, of $404,000 and $1,212,000 for
the three and nine months ended March 31, 1999, respectively. General and
administrative expenses will continue to increase with the addition of other
administrative personnel and an expanded scale of operations associated with the
development of multiple technologies.
8
<PAGE> 9
Interest income amounted to $431,000 and $327,000 for the nine months
ended March 31, 1999 and 1998, respectively. The increase in interest income
reflects the proceeds of the Company's Private Placement in November 1997.
Fluctuation will continue to occur quarter to quarter due to changes in the
investment balance.
LIQUIDITY AND CAPITAL RESOURCES
At March 31, 1999, the Company had cash, cash equivalents and
investments of $8,595,000. Cash and cash equivalents is comprised primarily of
the proceeds from the Company's Private Placement in November 1997.
The Company believes that with its current cash position, its financial
resources are adequate for its operations for at least the next 15 months. The
Company's future capital requirements will depend on numerous factors which
cannot be quantified and many of which the Company cannot control, including
continued progress in its research and development activities, progress with
pre-clinical studies and clinical trials, prosecuting and enforcing patent
claims, technological and market developments, the ability of the Company to
establish product development arrangements, the cost of manufacturing scaleup,
effective marketing activities and arrangements, and licensing or acquisition
activity. The Company may seek to obtain additional funds through equity or debt
financing, collaborative or other arrangements with corporate partners and
others, and from other sources. No assurance can be given that necessary
additional financing will be available on terms acceptable to the Company, if at
all. If adequate additional funds are not available when required, the Company
may have to delay, scale back or eliminate certain of its research, drug
discovery or development activities or certain other aspects of its operations
and its business will be materially and adversely affected.
The Company plans to invest significant resources in its research and
development activities and continue to add new personnel due to increased
business activities. The Company anticipates incurring additional losses over at
least the next several years, and such losses are expected to increase as the
Company expands its research and development activities relating to the
Purgative Product, Thrombospondin Technology and Fc Receptor Technology. To
achieve profitability, the Company, alone or with others, must successfully
develop and commercialize its technologies and products, conduct pre-clinical
studies and clinical trials, obtain required regulatory approvals and
successfully manufacture, introduce and market such technologies and products.
The time required to reach profitability is highly uncertain, and there can be
no assurance that the Company will be able to achieve profitability on a
sustained basis, if at all.
IMPACT OF YEAR 2000
Many existing computer programs and systems, including certain of those
used by the Company for its own internal purposes and those used by its
financial institutions, suppliers, vendors and others, use only two digits to
identify the year in the date field. These programs were designed and developed
without considering the impact of the upcoming change in the century. If not
corrected, computer applications that utilize this two-digit format could fail
or create erroneous results by or at the year 2000 ("Y2K").
The Company has identified three main areas of Y2K risk:
1. The Company's internal computer systems could be
disrupted or fail, causing an interruption or decrease in
productivity in the Company's operations;
2. The computer systems of third parties with whom
the Company regularly deals, including but not limited to its
financial institutions, suppliers, vendors, utilities, and
others ("Material Third Parties") could be disrupted or fail,
causing an interruption or decrease in the Company's ability
to continue its operations;
3. The Company's university-based research programs
could be disrupted, delayed or harmed due to the reliance on
computer based scientific instruments and scientific databases
which the Company has no control over.
The Company is currently evaluating the nature and extent of the Y2K
issues related to its internal systems. An initial evaluation indicates that the
process of making the Company's internal systems (which consist of a financial
system for the accounting office and a network system for internal and external
communications) Y2K compliant should be substantially completed with respect to
these systems before June 30, 1999.
9
<PAGE> 10
If any of the Company's Material Third Parties are not Y2K compliant
and their noncompliance causes a material disruption to any of their businesses,
the business of the Company could be materially adversely impacted. These
disruptions could include, among other things: a financial institution's
inability to process checks drawn on the Company's bank accounts, accept
deposits or process wire transfers; a supplier's, vendor's or financial
institution's business failure; an interruption in deliveries of supplies from
vendors; a loss of voice and data connections the Company uses to share
information; a loss of electric power to the Company's facilities; and other
interruptions to the normal conduct of business by the Company, the nature and
extent of which the Company cannot foresee. The Company will continue to
evaluate the nature and extent of this risk, but at this time is unable to
determine the probability that any of such risks will be realized, or if they
are, the nature or length thereof, or effect, if any, they may have on the
Company.
The Company is in the process of evaluating the extent to which Y2K
impacts its university-based sponsored research programs. General discussions
with university employees indicate that Y2K disruptions could include loss of
scientific data, inability to obtain supplies for scientific experiments, the
university's inability to process deposits to support research and all other
risks disclosed above for the university's suppliers, and vendors. The
universities are in the process of addressing their own Y2K issues and the
Company has no control as to the outcome of these matters.
The Company has incurred costs to date of approximately $10,000 to
remediate the Y2K impact. The Company anticipates spending nominal amounts for
computer consulting to fix any potential issues in its internal systems.
While the Company believes that it is addressing the Y2K issue, there
can be no assurance that the Company's Y2K analyses will be completed on a
timely basis, or that the costs and liabilities associated with the Y2K issue
will not materially adversely impact the business, prospects, revenues or
financial position of the Company. The Company is uncertain as to the worst case
Y2K scenario and has not yet developed a contingency plan to handle this worst
case scenario.
NEW ACCOUNTING PRONOUNCEMENTS
In June 1998, the FASB issued SFAS No. 133, "Accounting for Derivative
and Hedging Activities," which establishes accounting and reporting standards
for derivative instruments, including certain derivative instruments imbedded in
other contracts (collectively referred to as derivatives) and for hedging
activities. Statement No. 133 is effective for all fiscal quarters of fiscal
years beginning after June 15, 1999. As the Company does not currently engage or
plan to engage in derivative or hedging activities, there will be no impact to
the Company's results of operations, financial position or cash flow upon the
adoption of this standard.
10
<PAGE> 11
PART II -- OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS.
Not applicable.
ITEM 2. CHANGES IN SECURITIES AND USE OF PROCEEDS.
Not applicable.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES.
Not applicable.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.
Not applicable.
ITEM 5. OTHER INFORMATION.
Not applicable.
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
(a) Exhibits.
27 Financial Data Schedule
(b) Reports on Form 8-K
None
11
<PAGE> 12
SIGNATURES
In accordance with the requirements of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned thereunto duly
authorized.
INKINE PHARMACEUTICAL
COMPANY, INC.
Date: May 14, 1999 /s/ ROBERT F. APPLE
----------------------------
Robert F. Apple
Chief Financial Officer
12
<PAGE> 13
EXHIBITS
27 Financial Data Schedule
13
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
ACCOMPANYING FINANCIAL STATEMENTS AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE
TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<CIK> 0000929547
<NAME> INKINE PHARMACEUTICAL
<MULTIPLIER> 1,000
<CURRENCY> U.S. DOLLARS
<S> <C>
<PERIOD-TYPE> 9-MOS
<FISCAL-YEAR-END> JUN-30-1999
<PERIOD-START> JUL-01-1998
<PERIOD-END> MAR-31-1999
<EXCHANGE-RATE> 1
<CASH> 2,300
<SECURITIES> 6,295
<RECEIVABLES> 0
<ALLOWANCES> 0
<INVENTORY> 0
<CURRENT-ASSETS> 8,716
<PP&E> 271
<DEPRECIATION> 56
<TOTAL-ASSETS> 8,931
<CURRENT-LIABILITIES> 645
<BONDS> 0
0
0
<COMMON> 2
<OTHER-SE> 8,286
<TOTAL-LIABILITY-AND-EQUITY> 8,931
<SALES> 0
<TOTAL-REVENUES> 0
<CGS> 0
<TOTAL-COSTS> 0
<OTHER-EXPENSES> 6,729
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 0
<INCOME-PRETAX> (6,298)
<INCOME-TAX> 0
<INCOME-CONTINUING> (6,298)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (6,298)
<EPS-PRIMARY> (.28)
<EPS-DILUTED> (.28)
</TABLE>
